Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole genome sequence

Tuberculosis (TB) caused by the pathogenic agent of Mycobacterium tuberculosis (Mtb), remains a major global health threat. There were approximate 10 million new TB cases and 1.40 million deaths in the world in 2018 (World Health Organization, 2019). Moreover, about half a million of new cases were rifampicin-resistant TB, of which 78% had multidrug-resistant (MDR) TB (World Health Organization, 2019). Although the treatment success rate can reach up to 85% after standard 2HRZE/4HR (a 2-month intensive phase of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by a 4-month continuation phase of rifampin and isoniazid) anti-TB treatment, the treatment cycle is too long to obtain excellent compliance conducing to relapse and drug resistance.

Source: International Journal of Infectious Diseases - September 18, 2021 Category: Infectious Diseases Authors: Jing Bi, Qinglong Guo, Xiangdong Fu, Juan Liang, Lidong Zeng, Min Ou, Juanjuan Zhang, Zhaoqin Wang, Yicheng Sun, Lei Liu, Guoliang Zhang Source Type: research